CA-ALKIRA
22.11.2021 10:02:09 CET | Business Wire | Press release
Alkira Inc. has appointed Exclusive Networks, a global trusted cybersecurity specialist for digital infrastructure, as a distributor for its cloud networking as-a-service platform (CNaaS).
The deal makes Alkira’s CNaaS platform Cloud Services Exchange (CSX) available through Exclusive’s global partner ecosystem spanning 40 countries across five continents. It also underlines Exclusive’s commitment to growing its cloud portfolio in a market estimated by IDC to be on track for $1.3 trillion by 20251 .
Exclusive Networks (EXN), which posted gross sales of €2.9 billion in 2020, completed a successful Initial Public Offering and listing on Euronext Paris in September this year. The company has partnerships with some of the world’s largest and most successful cybersecurity, networking and cloud infrastructure vendors, including Fortinet, Nutanix, Palo Alto Networks, Rubrik and Sentinel One. It provides cybersecurity platforms, cloud solutions and associated value-add professional services through an extensive global partner network of specialist resellers, MSPs, CSPs, telcos and systems integrators.
Alkira has appointed Paul Couturier as Senior VP International to spearhead its expansion in the EMEA and APAC regions. Couturier is an IT industry veteran who has previously held senior management roles growing international markets for Efficient Networks, TippingPoint, Cyan, LightCyber and Palo Alto Networks. In his latest role, he managed IntSights from its European debut to its acquisition by Rapid 7.
Amir Khan, Co-Founder and Chief Executive Officer of Alkira, said: “Our vision is to simplify networking in the cloud era. As the CNaaS pioneer, Alkira has eliminated the complexities and costs of building and operating networks and seamlessly integrated cloud, multi-cloud and legacy systems – no hardware, no data center, no need to ship anything. Exclusive Networks is an ideal partner for Alkira, not only because it provides us with access to their first-class global network, but because we have a shared vision of an as-a-service future.”
Andy Travers, Executive Vice President, Worldwide Sales and Marketing for Exclusive Networks, said: “Our success has been built on bringing together best in class cybersecurity, networking and automation solutions. In the cloud era, the challenge for customers is how to integrate and manage these resources in an increasingly complex environment, while controlling costs and moving the business forward. With nothing more than a few mouse clicks, Alkira’s CNaaS enables secure hybrid cloud and multi-cloud networks to be set up in hours rather than months, and puts customers, not the big cloud providers, in the driver’s seat.
“Migration of enterprise applications to the cloud is set to double in the next two years, according to Gartner2 , so it seems inevitable that networking infrastructure will follow the same trend. Just as Alkira’s founders pioneered the SD-WAN market, we now believe they are showing the way in cloud networking.”
Alkira’s CNaaS platform simplifies provisioning, connectivity and end-to-end management of networks across cloud environments, including the integration of firewalls, IPS/IDS, and load balancers, as well as enhancing the capabilities of legacy SD-WAN solutions. It enables a flexible, unified approach to secure, high-performance networking in which customers only pay for the capacity they use, and the network automatically scales to meet changing patterns of usage and demand.
About Alkira
Alkira® developed the Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira CSX seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of integrated solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.alkira.com or follow us @AlkiraNet
(Alkira® and Alkira Cloud Services Exchange® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.)
About Exclusive Networks
Exclusive Networks is a global trusted cybersecurity specialist for digital infrastructure helping to drive the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models. The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to deliver partner value. With offices in 40 countries and the ability to service customers in over 150 countries across five continents, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. Learn more at www.exclusive-networks.com or follow us @EXN_Networks
1
IDC Forecasts Worldwide "Whole Cloud" Spending to Reach $1.3 Trillion by 2025
2
Market Guide to Cloud Networking Software, Gartner, May 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
